retatrutide side effects clinical trial results Lilly's triple agonist achieves 16.8% weight loss in phase 3 1 Month Retatrutide Results: Clinical

Chan DC, Watts GF, Ng TWK, Yamashita S, Barrett PHR

This is because in addition to reducing and controlling appetite, it also stimulates another hormone, GIP, which is thought to improve how the body breaks down sugar and fat

By staying informed and working closely with healthcare professionals, you can navigate these common challenges with confidence

Certainly, there is also great interest in looking into the cardiovascular benefits of GLP1 medications not only in diabetic populations but also in people without diabetes who exhibit risk factors for cardiovascular disease

The results from the other three clinical trials have been similarly mixed, and because they did not use the rigorous, controlled-trial methodology used in the 2017 study, it is unwise to integrate or compare results

If you have any medical concerns or conditions, please consult with a physician or other healthcare provider